The federal government will roll out the first phase of CCP virus vaccinations in the coming weeks; however, there are concerns over Pfizer’s limited supply as primary vaccine choice Oxford-AstraZeneca faces scrutiny. Chief Medical Officer Paul Kelly has stressed that it is not a question of whether one vaccine is better than the other but one of availability under the circumstances. “[W]e’ve had so few cases in Australia, so there will be very few people with the immunity that comes from having had the illness … in many ways, Australia is at more risk from that point of view.” Professor Kelly said in a press conference on Wednesday. He said it comes down to which vaccine is available to save lives and protect lives this year and “the answer to that is one we can make here.” The federal government has been forced to respond to criticism about the rollout …